OpenLB
Open Library of Bioscience
Advanced Search
Journal of virology
Mar 18, 2025;99 (3): e0231924.

Interactions between human immunodeficiency virus and human endogenous retroviruses.

Mengying Li, Fengting Yu, Baoli Zhu, Jiang Xiao, Chang Yan, Xiaojie Yang, Xuelei Liang, Fang Wang, Hanxi Zhang, Fujie Zhang
Author Information
  1. Mengying Li: Medical School, University of the Chinese Academy of Sciences, Beijing, China. ORCID
  2. Fengting Yu: Medical School, University of the Chinese Academy of Sciences, Beijing, China.
  3. Baoli Zhu: CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. ORCID
  4. Jiang Xiao: Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  5. Chang Yan: Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  6. Xiaojie Yang: Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  7. Xuelei Liang: Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  8. Fang Wang: Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  9. Hanxi Zhang: Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  10. Fujie Zhang: Beijing Ditan Hospital, Capital Medical University, Beijing, China. ORCID
PMID: 39918304 DOI: 10.1128/jvi.02319-24

Abstract

Human immunodeficiency virus (HIV), a retrovirus of the Lentivirus genus, targets CD4 T cells, causing immune dysfunction and AIDS. Approximately 8% of the human genome consists of human endogenous retroviruses (HERVs), ancient retroviral remnants that may interact with HIV. Despite antiretroviral therapy, challenges such as drug resistance, poor immune reconstitution (PIR), and reservoirs remain. This GEM discusses the impact of HIV on HERVs, the potential roles of HERVs in PIR and reservoirs, and provides insights into future research directions.

Keywords

HIV reservoir human endogenous retroviruses (HERVs) human immunodeficiency virus (HIV) poor immune reconstitution (PIR)

References

  1. Cell. 2015 Jan 29;160(3):420-32 [PMID: 25635456]
  2. J Virol. 2011 Nov;85(21):11526-31 [PMID: 21880743]
  3. AIDS Res Hum Retroviruses. 1992 Nov;8(11):1909-17 [PMID: 1489579]
  4. Genome Biol. 2001;2(6):REVIEWS1017 [PMID: 11423012]
  5. Retrovirology. 2017 Apr 26;14(1):27 [PMID: 28446240]
  6. J Virol. 2008 Oct;82(19):9329-36 [PMID: 18632860]
  7. AIDS Res Hum Retroviruses. 2007 Sep;23(9):1083-6 [PMID: 17919102]
  8. Clin Diagn Lab Immunol. 1999 Nov;6(6):783-6 [PMID: 10548563]
  9. J Virol. 2014 Oct;88(19):11108-20 [PMID: 25056891]
  10. J Immunol. 2014 Aug 15;193(4):1544-8 [PMID: 25024383]
  11. Trends Microbiol. 2023 Sep;31(9):933-946 [PMID: 37019721]
  12. Biochemistry. 1998 Dec 8;37(49):17137-44 [PMID: 9860826]
  13. Retrovirology. 2019 Dec 16;16(1):40 [PMID: 31842941]
  14. J Virol Methods. 2006 Sep;136(1-2):51-7 [PMID: 16678919]
  15. J Neurovirol. 2017 Aug;23(4):587-592 [PMID: 28474333]
  16. EMBO J. 2019 Jun 17;38(12): [PMID: 31068361]
  17. Bioessays. 2000 Feb;22(2):161-71 [PMID: 10655035]
  18. Proc Natl Acad Sci U S A. 2020 Apr 7;117(14):7905-7916 [PMID: 32193341]
  19. Viruses. 2020 Apr 23;12(4): [PMID: 32340287]
  20. Front Immunol. 2019 Jan 22;9:3092 [PMID: 30740110]
  21. Curr Opin HIV AIDS. 2016 Jul;11(4):417-23 [PMID: 27078619]
  22. Mem Inst Oswaldo Cruz. 2024 Sep 16;119:e240071 [PMID: 39292108]
  23. Retrovirology. 2017 Aug 22;14(1):41 [PMID: 28830571]
  24. Lancet Infect Dis. 2011 Jul;11(7):516-24 [PMID: 21600849]
  25. Int J Cancer. 2015 Sep 15;137(6):1249-57 [PMID: 24890612]
  26. Front Immunol. 2021 Mar 25;12:638010 [PMID: 33868264]
  27. Front Microbiol. 2023 Aug 07;14:1236460 [PMID: 37608956]
  28. Trends Microbiol. 2024 Apr;32(4):342-354 [PMID: 37802660]
  29. Sci Rep. 2018 Jan 12;8(1):629 [PMID: 29330412]
  30. PLoS One. 2014 Jul 02;9(7):e97984 [PMID: 24988390]
  31. Retrovirology. 2014 Jan 28;11:10 [PMID: 24472118]
  32. Chin Med J (Engl). 2022 Nov 20;135(22):2667-2676 [PMID: 36719355]
  33. Retrovirology. 2015 Mar 24;12:27 [PMID: 25886562]
  34. Science. 2016 Mar 4;351(6277):1083-7 [PMID: 26941318]
  35. J Virol. 2001 Apr;75(7):3488-9 [PMID: 11238877]
  36. J Mol Biol. 2020 Dec 4;432(24):166711 [PMID: 33197463]
  37. J Virol. 2014 Aug;88(16):8924-35 [PMID: 24872592]
  38. Signal Transduct Target Ther. 2023 Oct 6;8(1):381 [PMID: 37798292]
  39. AIDS. 2014 Nov 28;28(18):2659-70 [PMID: 25250834]
  40. J Med Virol. 2023 Jan;95(1):e28350 [PMID: 36428242]
  41. J Immunol Res. 2021 Sep 29;2021:7316456 [PMID: 34631899]
  42. Retrovirology. 2012 Jan 16;9:6 [PMID: 22248111]
  43. AIDS Res Hum Retroviruses. 1993 Jul;9(7):687-94 [PMID: 8396402]
  44. Nucleic Acids Res. 2020 Nov 4;48(19):10890-10908 [PMID: 33021676]
  45. J Med Virol. 2000 Dec;62(4):435-44 [PMID: 11074471]
  46. J Biol Chem. 2006 Nov 10;281(45):34574-91 [PMID: 16935861]
  47. Front Microbiol. 2021 May 17;12:662573 [PMID: 34079529]
  48. J Clin Invest. 2012 Dec;122(12):4473-89 [PMID: 23143309]
  49. J Leukoc Biol. 2020 Apr;107(4):597-612 [PMID: 31965635]
  50. J Virol. 2011 Jul;85(14):6977-85 [PMID: 21525339]
  51. AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):1973-80 [PMID: 11153080]
  52. J Virol. 2012 Aug;86(15):7790-805 [PMID: 22593154]
  53. Nature. 2022 Jan;601(7893):440-445 [PMID: 34794168]
  54. Acta Biochim Pol. 1996;43(4):583-92 [PMID: 9104494]
  55. mBio. 2023 Feb 28;14(1):e0328022 [PMID: 36645307]
  56. Immunity. 2012 Nov 16;37(5):867-79 [PMID: 23142781]
  57. Front Immunol. 2022 Nov 23;13:1057791 [PMID: 36518758]
  58. J Infect Dis. 2023 Nov 28;228(11):1583-1591 [PMID: 37592824]
  59. PLoS One. 2012;7(8):e41021 [PMID: 22879884]
  60. Ann Oncol. 2018 Nov 1;29(11):2183-2191 [PMID: 30239576]
  61. J Virol. 2012 Jan;86(1):262-76 [PMID: 22031938]
  62. Immunity. 2019 Mar 19;50(3):629-644.e8 [PMID: 30737147]
  63. AIDS Res Hum Retroviruses. 2007 Jan;23(1):116-22 [PMID: 17263641]
  64. PLoS Pathog. 2007 Nov;3(11):e165 [PMID: 17997601]
  65. Virology. 2017 Sep;509:52-59 [PMID: 28605635]
  66. J Virol. 2012 Oct;86(20):11194-208 [PMID: 22855497]
  67. Cancers (Basel). 2020 Mar 06;12(3): [PMID: 32155827]
  68. Front Immunol. 2019 Dec 18;10:2858 [PMID: 31921128]
  69. Clin Vaccine Immunol. 2012 Feb;19(2):288-92 [PMID: 22205657]
  70. Retrovirology. 2013 Feb 09;10:16 [PMID: 23394165]
  71. Microbiol Spectr. 2023 Mar 2;:e0443822 [PMID: 36861980]
  72. Microbiol Spectr. 2023 Dec 12;11(6):e0137923 [PMID: 37811936]
  73. Cell. 2016 Sep 22;167(1):219-232.e14 [PMID: 27662090]
  74. Cell Rep. 2020 Mar 31;30(13):4528-4539.e4 [PMID: 32234485]
  75. Front Immunol. 2022 Oct 17;13:1026070 [PMID: 36325329]
  76. Viruses. 2022 Dec 24;15(1): [PMID: 36680099]

Grants

  1. 2017-G14/The John Martin Foundation

MeSH Term

Humans
Endogenous Retroviruses
HIV Infections
CD4-Positive T-Lymphocytes
HIV-1
HIV
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0humanHIVHERVsimmunodeficiencyvirusimmuneendogenousretrovirusesPIRpoorreconstitutionreservoirsHumanretrovirusLentivirusgenustargetsCD4TcellscausingdysfunctionAIDSApproximately8%genomeconsistsancientretroviralremnantsmayinteractDespiteantiretroviraltherapychallengesdrugresistanceremainGEMdiscussesimpactpotentialrolesprovidesinsightsfutureresearchdirectionsInteractionsreservoir

Similar Articles

Cited By

No available data.